Contact information: Lundberg Lab, Medicinareg. 9c, 40530 Göteborg; office 1405.
RESEARCH
Theoretical biophysical chemistry in form of computer based modeling of various biochemical processes and systems. Our focus has for a long time related to DNA damage processes, cancer and drug design; often linked to radical and photochemistry. In recent years, we have explored increasingly larger systems, including diffusion across biological membranes, drug loaded liposomes, derivation of protein structures and studies of their mechanisms, modeling of protein-protein complexes, and development of new inhibitors in cancer treatment and as antibiotics.
We utilize a wide range of methods in our research, from DFT and QM/MM to molecular dynamics simulations and bioinformatic tools such as VHTS/docking and homology modeling.
ResearcherID: D-1226-2012
Current research group: 1 researcher (Dr Anna Reymer), 3 PhD students (Antonio Carlesso, Sonali Chavan, Johanna Hörberg), and several Master students, visiting researchers and PhD students.
TEACHING
General chemistry (KEM011)
Analytical pharmaceutical chemistry (KER210)
General pharmaceutical chemistry (KER220)
Basic Molecular Modeling (KEM552)
Lectures in various courses such as KEM350 and KMG045.
COMMISSIONS OF TRUST
Vice head of department for research.
Chemistry representative in C3SE board.
Spokesperson for the Division of Biochemistry and Structural Biology.
Participates in H2020 MSCA-ITN project TRAIN-ERS.
Participates in H2020 MCSA-RISE project EPIC.
Member of UGOT CARe (Center for Antibiotics Resistance Research).
MERITS
Leif Eriksson studied Chemistry at Stockholm university and University of Sussex 1985-1988. He received his PhD in Quantum chemistry at Uppsala Universitet (1992), followed by a postdoctoral fellowship from the Swedish research council VR (then 'NFR') to go to Dalhousie University, Canada, 92/93. He most recently comes from NUI Galway, Ireland, and holds the current professorship in physical chemistry at GU since 2011. He was awarded the 2017 Pedagogic price from the Science section of the Göta Student Union at University of Gothenburg.
Eriksson has published >250 peer reviewed research papers and some 20 review papers and book chapters, in the field of theoretical/computational (bio)chemistry. He holds the patents of a new pharmaceutical against skin cancer and for a new inhibitor of Vitmain A degradation, and is part owner of spin-out companies Santium Pharma, C26 Bioscience, and Cell Stress Discoveries. He is currently involved in the development of several new drugs, of which the first are in the patenting stage.
